High Accuracy
Shown in Clinical Performance Trial
SpotitEarly’s high accuracy in detecting early-stage cancer was demonstrated in the Rainbow Study, a large-scale clinical trial conducted in partnership with three leading healthcare institutions in Israel. Results were impressive both in terms of sensitivity and specificity. Two more trials are starting as we breathe…
Increasing Adoption of Cancer Screening
Accurate
94% SENSITIVITY & SPECIFICITY IN EARLY STAGE CANCER
Easy
A SIMPLE BREATH
SAMPLE COLLECTED AT HOME IN MINUTES
Accessible
AFFORDABLE, AVAILABLE TO EVERYONE, ANYWHERE
SpotitEarly’s technology aims to enable more frequent testing of much wider audiences at a fraction of the cost. We’re committed to saving lives and improving clinical outcomes for everyone, everywhere.
LET'S SPOTITEARLY TO SAVE MORE LIVES.
Human breath contains over 1,000 Volatile Organic Compounds or VOCs. Science has shown that VOCs represent rich sources of biomarkers associated with metabolic processes and diseases in the body, each identified by a significant odor signature, including cancer. SpotitEarly harnesses the science of scent to detect cancerous VOCs in exhaled breath samples.
THE SCIENCE
Breath Carries
the Odor Signature of Cancer
Nature's Intel Meets AI
Biosensors, Data Science, Biochemistry and Nanotechnology Join Forces
The most sophisticated odor sensors we can find as of today were actually designed by nature. But we’ve developed the key to transforming their signals into precise clinical-level information.
LUCID, our cutting-edge AI tech platform increases accuracy of results, offering a cancer pre-screening solution that is reliable, scalable, and with the proper resources, replicable around the globe.
The LUCID platform integrates Proprietary Hardware Devices and Software
While canines sniff breath samples with their highly sensitive olfactory system to detect cancer odor signatures, LUCID collects and analyzes thousands of data points every second, providing verification regarding the canine's detection signal.
Optimized
Interpretation
Validated
Conclusions
Constant
Learning
Optimized Interpretation
Adaptive Calibration
Constant Learning
As a cancer screening expert, I've rigorously reviewed the SpotitEarly solution's clinical validation. I am deeply impressed by its potential to revolutionize cancer screening. Its innovative approach and proven effectiveness set a new standard in early detection. I fully endorse SpotitEarly as a game-changer in our field.
Prof. Nadir Arber
HEAD OF THE INTEGRATED CANCER PREVENTION CENTER, TEL AVIV SOURASKY MEDICAL CENTER
Clinical Partners
University
of Pennsylvania
Tel Aviv Sourasky
Medical Center
Hadassah
Medical Center
Rambam Health
Care Campus
Assuta
Hospital
As an expert in scent nanotechnology, I have closely followed the clinical validation of the SpotitEarly solution. The seamless integration of natural scent detection principles with advanced AI is a true breakthrough in the field. Utilizing Volatile Organic Compounds (VOCs) for cancer detection, is an innovative approach that marks a major leap forward. I am excited about its potential to transform cancer detection.
Dr. Reef Einoch Amor
PHD, DIRECTOR OF CHEMICAL ANALYSIS, SpotitEarly
Accessible to All, Anytime
Today, only 14% of cancers in the U.S. are diagnosed following a recommended screening test. With an easy-to-use breath collection kit now more people could potentially take the test at home and get pre-screened for multiple types of cancer even at early stages.
Key Benefits:
-
At-home collection
-
Non-invasive
-
Affordable and accessible
-
No side effects, no preparation needed
-
No clinic visits required
-
Online prescription, no appointments or lost work days
94% Accuracy
Very high sensitivity
and specificity in early stage cancer
Easy
A simple breath
sample collected at home in minutes
Accessible
Affordable, available to everyone,
anywhere